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INTRODUCTION 
 
Neurocutaneous syndromes are a group of genetically 
determined heterogeneous disorders that manifest with developmental 
abnormalities of the skin and the nervous system.  These disorders are 
believed to originate from the faulty differentiation of primitive 
ectoderm. The two most common neurocutaneous syndromes are 
Neurofibromatosis and Tuberous sclerosis. Sturge Weber syndrome, 
Ataxia telangiectasia and Epidermal naevus syndrome also occur 
commonly.  Most of the other neurocutaneous syndromes are rare. 
 
The cutaneous lesions usually appear at an early age and 
progress with time while neurological features usually manifest at a 
later age. The common neurological manifestations include learning 
disability, seizures, developmental delay and focal deficits but the 
expected neurological manifestation depends on the specific disease.  
Neuroimaging studies are helpful in the early diagnosis of 
neurological involvement.  They also help to assess the extent of 
neurological involvement and to predict the prognosis.  
 
Our study was designed to observe the manifestations in 
neurocutaneous syndromes at the time of diagnosis and to assess the 
extent of nervous system involvement using imaging studies. 
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AIM OF THE STUDY 
 
1. To study the prevalence of various Neurocutaneous disorders.   
2. To study the clinical manifestations of Neurocutaneous 
disorders.  
3. To evaluate the incidence of neurological complications in 
patients with Neurocutaneous disorders. 
4. To study the radiological features in Neurocutaneous 
disorders. 
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REVIEW OF LITERATURE 
 
Neurocutaneous disorders are a group of genetic disorders that 
manifest with developmental lesions of the skin and the nervous 
system. Van der Hoeve, a Dutch ophthalmologist in the 19
th
 century 
was the first to recognize the association of neurologic disease with 
cutaneous and retinal lesions.  He coined the term phakomatosis 
(Greek phakos meaning spot, lens).  He first included 
neurofibromatosis and turberous sclerosis but when he included Sturge 
Weber syndrome which does not present with hamartomas or 
phakomas, the term phakomatosis became inappropriate. The term 
neurocutaneous syndrome was introduced by Yakovlev and Guthrie in 
1931 to describe these group of disorders.  These disorders may be 
inherited or sporadic
1
. 
 
The neurocutaneous syndromes can be classified as follows
2
: 
I. Autosomal dominant   
1. Neurofibromatosis 1 
2. Neurofibromatosis 2 
3. Tuberous sclerosis 
4. Von Hippel-Lindau disease 
5. Hereditary hemorrhagic telangiectasia  
6. Ehlers-Danlos syndrome type IV 
4 
 
II. Autosomal recessive 
1. Ataxia-telangiectasia 
2. Xeroderma Pigmentosum 
3. Cerebrotendinous xanthoma 
4. Pseudoxanthoma elasticum 
 
III. X-linked dominant 
1. Incontinentia pigmenti. 
2. Focal Dermal hypoplasia 
 
IV. X-linked Recessive 
1. Fabry’s disease 
2. Menkes’ syndrome 
 
V. Sporadic 
1. Sturge-Weber  syndrome 
2. Epidermal nevus 
3. Progressive facial hemiatrophy 
4. Hypomelanosis of Ito 
 
NEUROFIBROMATOSIS 
Neurofibromatosis is the most common neurocutaneous 
disorder. Two most common types are neurofibromatosis 1(NF1) and 
neurofibromatosis 2 (NF2)
3
. 
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RICCARDI’S Classification System of Neurofibromatosis4 
 
NF Inheritance Clinical Features 
NF1 AD Gene  
17q11.2 
Café-au-lait spots (CALM), NF, axillary or inguinal 
freckles, Lisch nodules, bone changes, optic glioma. 
NF2 AD, Gene 
22q12.2 
Bilateral vestibular schwannoma, multiple CNS 
Tumours – meningiomas, spinal astrocytomas, 
ependymomas, retinal hamatoma, cataracts. 
NF3 AD (or) 
Sporadic 
Features of NF1 and NF2 including some CALM, 
freckling, NF, CNS or paraspinal tumours, absence of 
vestibular shawannoma and lisch nodules.  
NF4 Sporadic Atypical ,a variant of type II 
NF5 Sporadic / A.D Segmental-one quadrant /one side of the body.  It can 
be bilateral segmental NF with or without CALM 
NF6 AD Multiple CALM, but no neurofibroma. To diagnose 
this two generation should be affected. 
NF7 Sporadic Onset at end of 3
rd
 decade or later. No Lisch nodules. 
Lesions appear after immunosuppressant.  
NF8  NF not fitting into any of the above.  
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Neurofibromatosis 1  
(Von Recklinghausen’s disease/peripheral neurofibromatosis) 
 NF1 constitutes 96% of all cases of neurofibromatosis and the 
prevalence is 1:3,000. 
 
Genetics 
It is an autosomal dominant disease with variable expression 
and near complete penetrance. It is associated with NF1 gene mutation 
on chromosome 17q11.2. NF1 gene is a tumor suppressor gene that 
codes for neurofibromin. Absence of neurofibromin leads to increased 
Ras activity and cell proliferation, resulting in neoplasms. 
Neurofibromin also regulate cyclic adenosine monophosphate levels. 
 
Clinical Features 
 
CUTANEOUS MANIFESTATIONS 
1. Neurofibromas 
Neurofibromas are hallmark findings of NF1 that often present 
at puberty and increase in number and size with age. They may be 
circumscribed (cutaneous or subcutaneous) or non circumscribed 
(plexiform). They are generally benign, but plexiform neurofibromas 
may undergo malignant transformation.  They are commonly located 
near a spinal radicle. 
7 
 
Plexiform neurofibromas 
Plexiform neurofibromas are specific to NF1 and are a major 
cause of morbidity. These lesions are irregular, thickened, non-
circumscribed and disfiguring. They can envelop vital structures and 
can involve the orbit. Malignant peripheral nerve sheath tumors may 
develop from plexiform neurofibromas. 3% to 5% of NF1 patients 
develop malignant peripheral nerve sheath tumors
5
 
 
2. Café-au-lait Macules (CALM) 
They are sharply defined light brown macules and patches of 
varying sizes with smooth borders. They are found all over the body 
except scalp, palms and soles and eyebrows. CALM are the earliest to 
appear
6
. 
 
3. Freckling 
Freckles are tan brown macules of 1-4 mm in diameter. Axillary 
freckling is called Crowe’s sign. It is diagnostic when present in groin 
and axilla.   Palmar freckling can also occur
7
. 
 
NEUROLOGICAL MANIFESTATIONS 
Neurological features include cognitive deficits and learning 
disabilities
8
. There can be pain in specific nerve distribution due to 
presence of a neurofibroma. Visual complaints related to optic glioma 
8 
 
are common. Seizures may be due to intracranial tumors. Headaches 
may occur due to migraine or intracranial pressure. Progressive 
neurologic deficits can occur due to neurofibroma or other tumors. 
Moyamoya disease, intracranial aneurysms and migraine are other 
neurological features associated with NF1. 
 
Nervous system tumours  
Optic nerve gliomas are the most common CNS tumour in NF1. 
Low-grade pilocytic astrocytoma arising from optic nerve or chiasma 
may be an incidental finding or may present as progressive loss of 
vision and optic atrophy. Other tumours that can occur are 
parenchymal astrocytomas, meningiomas, pilocytic astrocytoma of the 
brainstem and cerebellum. 
 
Ocular manifestations 
Pigmented iris hamartomas otherwise called as Lish nodule 
occurs in 85to 90%. They are brownish translucent spots present 
bilaterally
9
. 
  
Skeletal Manifestations 
 They are sphenoid wing dysplasia, kyphoscoliosis
10
, 
pseudoarthrosis, vertebral scalloping and macrocephaly. Congenital 
pseudo arthrosis is commonly seen in tibia or radius.  Short stature due 
9 
 
to growth hormone deficiency has been reported. Thinning of cortex 
resulting in pathological fractures are common. 
 
Pulmonary Change (10-20%) 
Firbrosing alveolitis and interstitial fibrosis are the pulmonary changes   
associated with neurofibromatosis. 
 
Gastro Intestinal (20%) 
Constipation due to dysfunction of colonic musculature or 
colonic neurofibroma can occur. Recurrent Haemorrhages, obstruction 
or intussuception frequently involving the jejunum and stomach are 
the other manifestations. 
 
Other features 
 Schwanoma, pheochromocytoma, neuroblastoma, 
ganglioglioma, Juvenile chronic myeloid leukemia and 
rhabdomyosarcoma are the other tumours associated tumours 
associated with neurofibromatosis. Other associated features are 
hypertension, proptosis, gynaecomastia, glaucoma and renal artery 
stenosis. 
 
10 
 
National institute of health Diagnostic Criteria for 
Neurofibromatosis 1
11
 
Two or more of the following: 
1. ≥6 café au lait spots 
2. ≥2 neurofibromas of any type or ≥1 plexiformneurofibroma 
3. Freckling (Crowe’s sign) in axilla or groin 
4. Optic glioma 
5. ≥2 Lisch nodules (benign pigmented irishamartomas) 
6. Distinctive bony lesion 
7. First-degree relative with neurofibromatosis type 1 
 
RADIOLOGICAL FEATURES IN NF 1 
Approximately 60% to 78% of patients with NF1 have 
increased signal intensities within the basal ganglia, thalamus, 
brainstem, and cerebellum in T2-weighted MRIs. These areas are not 
routinely visible with CT. The origin and significance of these 
radiographic lesions are unclear. They are referred to as unidentified 
bright objects (UBOs).
 
 
CT Findings 
Plain CT brain shows Sphenoid dysplasia with associated 
enlargement of middle cranial fossa and optic nerve glioma presenting 
as ipsilateral proptosis and enlarged optic nerves/chiasm. Contrast CT 
11 
 
shows enhancing visual pathway gliomas. CT angiogram shows 
vascular dysplasias and aneurysm. 
  
MRI Findings 
 White matter (WM) lesions are variable intensity in T1  and 
hyperintense in T2. On contrast WM lesions usually don't enhance, 
Enhancement raises the concern of neoplasm. Plexiform lesions have 
variable enhancement. Excellent definition of plexiform and 
paraspinal neurofibromas are seen in STIR sequence. Optic nerve 
glioma are isointense or hyperintense. Best sequence for evaluation of 
visual pathway gliomas is T1 contrast. In MRS glioma have elevated 
choline peak. Spine imaging shows multiple level neurofibromas, 
dumbel tumour (characteristic of NF 1) and spinal cord compression. 
 
NEUROFIBROMATOSIS TYPE 1- MYELIN VACUOLIZATION 
 Myelin vacuolization is previously known as hamartoma. They 
composed of dysplastic neurons and microcysts and are found in 
nearly 80% of cases. Common sites are basal ganglia especially 
globuspallidus, optic radiation, internal capsule, brain stem and 
cerebellar & cerebral peduncles
12
.
  
 
 In MRI, most areas of myelin vacuolization are isointense or 
hyperintense on T1WI, whereas most astrocytomas are hypointense.  
12 
 
In T2 and FLAIR images they are hyperintense and shows increased 
diffusion on diffusion weighted imaging (DWI). They may grow until 
the 10 years of age without any mass effect or contrast enhancement, 
after which it starts regressing. Magnetic resonance spectroscopy 
(MRS) shows minimally elevated choline and slight reduction in N-
acetyl-aspartate (NAA) levels. 
 
 Radiography is useful in identifying sphenoid wing and 
occipital bone dysplasia and kyphoscoliosis. 
 
NEUROFIBRAMATOSIS TYPE2 
NF2 constitutes 3% of neurofibromatosis and the prevalence is 
1:40,000. 
 
Genetics 
 NF2 gene is a tumor suppressor gene located on chromosome 
22q12. It codes for merlin expressed in adult Schwann cells, 
meningeal cells and lens. 
 
 Clinical manifestations 
 Symptoms often present in the teenage. Vestibular schwannoma 
is a nerve sheath tumour that typically occurs bilaterally. Clinical 
presentation often includes progressive hearing loss, tinnitus and 
imbalance. 
13 
 
Associated features 
a. Spinal and cranial nerve (CN) schwannomas (CN V-XII) 
b. Intracranial meningiomas 
c. Spinal cord ependymomas, gliomas 
d. Posterior subcapsular cataracts (85% of patients) 
e. Retinal hamartomas 
f. Café au lait spots (45% of patients) 
g. Skin plaque like lesion (70% of patients) 
h. Mononeuropathy (CN VII most common) 
i. Seizures 
 
Diagnostic Criteria 
1. Bilateral eighth nerve tumor (shown by magnetic resonance 
imaging, computed tomography, or histological confirmation) 
or 
2. A first-degree relative with neurofibromatosis type 2 and a 
unilateral eighth nerve tumour or 
3. A first-degree relative with neurofibromatosis type 2 and any 
two of the following lesions: neurofibroma, meningioma, 
schwannoma, glioma, or juvenile posterior subcapsular 
lenticular opacity. 
 
14 
 
RADIOLOGY IN NF2 
CT Findings 
 Plain CT shows cerebellopontine angle (CPA) mass with or 
without widened internal acoustic meatus (IAC) which is isodense to 
hyperdense with contrast enhancement. Meningioma is high density 
dural based mass with extensive calcifications in choroid plexus and 
cortical surface with contrast enhancement. 
 
MRI Findings
13
  
Schwannomas are hypointense to isointense on T1 and rarely cystic 
change can be seen on   T2. Small intra canalicular lesions can be 
shown on high resolution T2WI. Diffuse homogeneous enhancement 
occurs. Vestibular schwannomas typically "bulge" into CPA cistern 
from IAC. MRS shows absent NAA peak. 
 
 Meningiomas are isointense to hypointense and occasional 
hyperintense foci from calcification with adjacent edema can be seen. 
Some meningiomas have restricted diffusion with diffuse 
enhancement of tumour. MRS shows absent NAA peak with or 
without lactate. 
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TUBEROUS SCLEROSIS (TSC) 
Synonyms: EPILOIA, BOURNEVILLE’S DISEASE 
TSC is as an autosomal dominant disorder with variable 
penetrance characterized by systemic hamartomas involving mostly 
the skin, nervous system, heart, eyes and kidneys. 
 
Genetics 
Two genes are responsible, TSC1 coding for hamartin at 
chromosome 9q34.3 and TSC2 coding for tuberin at 
chromosome16p13.3
14
. The clinical features of TSC1 and TSC2 
overlap since the two gene products form a single functional unit that 
is an upstream modulator in the mTOR (mammalian target of 
rapamycin) signaling pathway. Both gene products down regulate 
small G-protein Ras-homologue enriched in brain (RHEB) activity in 
this pathway.  TSC2 mutations appear more commonly than TSC1 in 
patients with subependymal nodules, mental retardation, renal 
angiomyolipomas and retinal phakomas. 
 
Cutaneous Features 
The cutaneous lesions of TSC include hypomelanotic macules, 
shagreen patch, ungual fibromas and facial angiofibromas. 
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1Ash leaf spots: Hypomelanotic macules occur in up to 90% of 
affected individuals. The lesions usually are present at birth but may 
be seen in the newborn only with an ultraviolet light. Other 
pigmentary abnormalities include confetti lesions (areas with stippled 
hypo pigmentation, typically on the extremities) and poliosis (a white 
patch or forelock) of the scalp, hair, or eyelids. Hypomelanotic 
macules are common in normals
15
. 
 
2. Facial angiofibromas (adenoma sebaceum): consist of vascular and 
connective tissue elements. Although considered specific for TSC, 
they are found in only three-fourths of affected individuals. The 
lesions typically become apparent during the preschool years as a few 
small red macules on the malar region. They gradually become 
papular, larger and more numerous, sometimes extending down the 
naso labial folds and chin. Laser therapy is useful   prior to puberty
16
. 
 
3. Shagreen patch: is most often found on the back or flank area and 
is usually considered specific for TSC.  It is an irregularly shaped, 
slightly raised or textured skin lesion. Only 20% to 30% of patients 
with TSC have one patch, which may not be seen in young children. 
 
4. Ungual fibromas are nodular or fleshy lesions that arise adjacent to 
(periungual) or underneath (subungual) the nails.  These can occur as a 
17 
 
single lesion after trauma in normal individuals. Ungual fibromas 
occur in only 15% to 20% of patients with TSC, more likely in 
adolescents or adults
17
. 
 
Neurological Features 
The predominant neurological manifestations of TSC are mental 
retardation, seizures, and behavioral abnormalities. It is due to 
abnormal neuronal migration along radial glial fibers and abnormal 
proliferation of glial elements. Neuropathological lesions of TSC 
include subependymal nodules (SENs) seen in 98% of patients, 
cortical and subcortical hamartomas (75%), areas of focal cortical 
hypoplasia and heterotopic gray matter
18
. 
 
Seizures 
 Seizures of various types occur in 80% to 90% of patients
19
. 
Most develop during the first year of postpartum, which is an indicator 
for autism and poor cognitive development. One third of children with 
TSC develop infantile spasms .Children with infantile spasms have 
more cortical lesions. Vigabatrin has been a more effective treatment 
option than adrenocorticotropin hormone (ACTH). Resective epilepsy 
surgery is a consideration in individuals with seizures localizing to a 
single tuber
20
. Most patients with mental retardation have epilepsy, but 
many have seizures with normal intelligence. The number of 
18 
 
subependymal lesions does not correlate with the clinical severity of 
TSC. 
 
 In addition to intellectual disability, many children with TSC 
have serious behavioral disorders. Autistic behavior, hyperkinesis, 
aggressiveness, and frank psychosis sometimes occur, either as 
isolated problems or in combination with epilepsy or intellectual 
deficit. 
 
Subependymal nodules (SENs) 
 SENs commonly arise from germinal matrix progenitors in the 
caudothalamic groove near the foramen of Monro. These lesions can 
grow over time, but usually only into adolescence, after which time 
they calcify. These remain asymptomatic unless they enlarge and 
transform into subependymal giant-cell astrocytomas (SEGAs) seen in 
15% of cases
21
. 
 
Cortical tubers 
 Tubers frequently extend from the ventricle wall to the cortical 
surface. Histology of these areas demonstrates disorganized cortical 
lamination and underlying abnormal myelination. Calcinosis is 
frequently present. Abnormal astrocytes of focal cortical dysplasias 
are termed balloon cells or giant cells for their abundant cytoplasm. 
19 
 
Renal manifestations (80%) 
 The common renal manifestations reported are renal 
angiomyolipoma,  aneurysmal dilatation of  renal arteries, renal artery 
stenosis and polycystic kidneys (12%). Hypertension in children with 
TSC can be due to renal parenchymal lesions like angiomyolipomas 
and cyst.  Malignant epitheloid renal angiomyolipoma in a patient 
with TSC has been reported.  This is related to a contiguous gene 
syndrome because mutations span both the TSC2 gene and the 
adjacent polycystic kidney disease gene (PKD). 
 
Cardiac Manifestation 
 Rhabdomyomas of the heart are common . 80% of all children 
presenting with Rhabdomyoma have TSC. Wolff-Parkinson-White 
syndrome and ventricular arrhythmias have also been reported. 
 
Diagnostic Criteria for Tuberous Sclerosis Complex
22
 
Major Features 
1. Facial angiofibromas or forehead plaque 
2. Nontraumaticungual or periungual fibroma 
3. Hypomelanotic macules 
4. Shagreen patch  
5. Multiple retinal nodular hamartomas 
6. Cortical tuber 
20 
 
7. Subependymal nodule 
8. Subependymal giant-cell astrocytoma 
9. Cardiac rhabdomyoma, single or multiple 
10. Lymphangiomyomatosis 
11. Renal angiomyolipoma 
 
Minor Features 
1. Multiple randomly distributed pits in dental enamel 
2. Hamartomatous rectal polyps 
3. Bone cysts 
4. Cerebral white-matter radial migration lines 
5. Gingival fibromas 
6. Non renal hamartoma 
7. Retinal achromic patch 
8. Confetti skin lesions 
9. Multiple renal cysts 
 
 Definite tuberous sclerosis complex: either 2 major features or1 
major feature plus 2 minor features. 
 Probable tuberous sclerosis complex: 1 major plus 1 minor 
feature. 
 Possible tuberous sclerosis complex: either 1 major feature or 2 
or more minor features. 
21 
 
CT Findings 
 In Plain CT sub ependymal nodule (SENs) are seen along 
caudo thalamic groove. Calcification is seen in 50%. Low density 
tubers are seen in cortical/sub cortical region. SEGA is evidenced by 
ventriculomegaly and contrast enhancement
23
. 
 
MRI Findings 
 SEN enhancement is more visible on MRI than on CT and 30-
80% enhance. In FLAIR, Streaky linear or wedge-shaped hyper 
intensities along radial migration lines from ventricle to cortex called 
radial bands are commonly seen in frontal then parietal region. Axial 
flair MRI better visualize tubers and SEN. SEGA is diagnosed by 
contrast enhancement and choline peak in MRS. PET scan shows 
reduced glucose metabolism in lateral temporal gyri in TSC  with 
autism patients. Rhabdomyomas are identifiable as early as 20 weeks 
gestation. 
 
STURGE-WEBER SYNDROME 
(Encephalotrigeminal angiomatosis) 
 It is a sporadic condition   characterized by leptomeningeal 
angiomatosis and ipsilateral facial cutaneous vascular malformation 
called port-wine nevus, usually in distribution of ophthalmic division 
of trigeminal nerve. Prevalence is 1:50,000. 
22 
 
 Pathology 
 Symptoms are generally related to leptomeningeal 
angiomatosis, a low-flow vascular malformation. They are 85% 
unilateral and are usually located in posterior parietal and occipital 
regions. They do not cause subarachnoid haemorrhage. 
 
Clinical Manifestations 
Port-wine nevus  
A cutaneous vascular malformation distributed in ophthalmic 
division of Cranial nerve V over forehead and upper eyelid or 
periorbital area usually unilateral, bilateral rarely. 
 
Seizures 
 Occur in up to 75% to 90% of patients with Sturge-Weber 
syndrome by the age of 3 years. Mean age at onset is 6 months. Onset 
of seizures occurs during first year of life in 75% of patients, before 2 
years in 86%, and before 5 years in 95%. Typically focal motor 
seizures occur but secondary generalized tonic clonic seizures may 
also develop.  Other types of seizures like atonic, tonic, myoclonic, or 
infantile spasms can also occur. Associated features are developmental 
delay, emotional and behavioural problems and mental retardation. 
 
 
23 
 
Focal deficits 
Hemiparesis (25% to 60%) occurs contra lateral to 
leptomeningeal angiomatosis due to chronic hypoxia
24
. Hemianopia 
can occur in up to 40% . Vascular steal phenomenon may develop 
around angioma, resulting in progressive calcification, gliosis, and 
atrophy. 
 
Developmental disorders 
Developmental disorders may occur in 50% to 75% of cases. It 
is more common in patients with bilateral angiomatosis. 
 
Ophthalmic features 
 Glaucoma can occur in eye ipsilateral to port-wine nevus, 
highest likelihood when both the upper and lower eyelid are involved.  
Other associated features are buphthalmos, choroidal hemangioma of 
eye. 
 
Subtypes 
1. Type I: both facial and leptomeningeal angiomas; may have 
glaucoma. 
2. Type II: facial angioma alone; may have glaucoma. 
3. Type III: isolated leptomeningeal angiomatosis; usually no 
glaucoma. 
24 
 
CT Findings 
Plain CT shows progressive calcification of gyral or subcortical 
white matter and atrophy over parieto occipital region. In contrast CT, 
serpentine leptomeningeal enhancement is seen. 
 
MRI Findings 
 In early part atrophy of white matter, later white and gray 
matter atrophy. Gradient echo shows tram-track gyral calcifications 
with pial enhancement on contrast. MRV shows lack of superficial 
cortical veins and reduced flow in transverse sinuses and jugular veins 
with prominent deep collateral veins. PET scan shows progressive 
glucose hypometabolism and SPECT scan shows hypo perfusion. 
Angiography shows paucity of normal cortical veins, extensive 
medullary and deep collaterals
25
. 
Radiography of the skull shows Tram-track calcification. 
 
ATAXIA TELANGIECTASIA 
 ATM gene is located on chromosome 11q22-q23. ATM protein 
is located in the nucleus and has a role in cell cycle control and 
mitogenic signal transduction. 
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Clinical Features 
1. Telangiectasias are found in conjunctiva, nose, ear, neck, 
antecubital fossa, and popliteal fossa. Oculocutaneous 
telangiectasias usually occur after the onset of ataxia around 4 
to 6 years of age. Usual age of onset is between 1 and 2 years.  
2. Ataxia predominantly truncal is usually the first symptom, then 
appendicular ataxia and dysarthria occurs.  Ophthalmic features 
include jerky pursuit movements with loss of optokinetic 
nystagmus and limitation of upgaze, slow saccades and 
oculomotor apraxia. Rare associated neurological features are 
choreoathetosis, dystonia, large-fiber sensory (demyelinating) 
peripheral neuropathy, reduced or absent deep tendon reflexes, 
very rarely extensor plantar responses. Progressive distal 
muscle atrophy may occur later
26
. 
3. Predisposition to neoplasia, mainly leukemia or B-cell 
lymphoma occurs before age of 20 years. Sinopulmonary 
infections are the other associated features. 
 
Increased level of alpha feto protein, decreased serum levels of 
IgA, IgE, IgG, (IgG2) and increased levels of IgM may be found. 
Pathologically Cerebellar (vermis) atrophy,  cell loss  in inferior 
olivary nucleus, dentate nucleus, Purkinje cells, and granule cells, 
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degenerative changes in the spinal cord affecting the posterior and 
lateral columns and anterior horn cell may occur.  Imaging shows   
cerebellar vermian atrophy
27
. 
 
GIANT CONGENITAL MELANOCYTIC NAEVUS 
(NEUROCUTANEOUS MELANOSIS) 
It is a congenital disorder of melanotic cell development and 
migration characterized by cutaneous melanocytic nevi and a high risk 
of developing benign or malignant melanocytic tumours of the central 
nervous system. Accumulation of melanotic cells occurs in arachnoid 
and piamater, amygdala, cerebellum, thalamus, frontal lobes and basal 
brain. 
 
Clinical Manifestations 
1. 65% of patients have giant congenital melanocytic nevi (more 
than 20cm) present at birth over head and scalp. Presence of 
naevi over the back implies an increased likelihood of 
developing neurologic symptoms. Satellite nevi may occur 
around giant nevus (80%). Risk of developing melanoma is 5% 
to 15%. 
2. Neurological manifestations include leptomeningeal melanosis, 
intracranial melanoma and intracerebral or subarachnoid 
haemorrhage. Hydrocephalus may occur as a result of 
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accumulation of melanotic cells at basal subarachnoid cisterns. 
Other neurological features are seizures (44%), papilledema 
(31%), headaches (30%), mental retardation (18%), cranial 
nerve palsies, malformation of vertebral column, spinal cord, 
cerebrum and Dandy-Walker malformation. Leptomeningeal 
proliferation affecting spinal cord results in myelopathy and 
cauda equina syndrome
28
. 
3. Other associated neoplasms are embryonal rhabdomyosarcoma, 
malignant schwannoma in retroperitoneum and liposarcoma. 
 
Diagnostic Criteria 
1. Multiple (≥3) congenital nevi in association with meningeal 
melanosis or melanoma(in infant ≥ 9 cm  on scalp or ≥ 6 cm  
over body and in adult ≥ 20 cm) . 
2. Absence of malignant melanoma in any organ (including skin) 
other than central nervous system. 
 
Imaging 
Brain MRI may demonstrate T1 shortening in presence of 
melanin. Gadolinium enhancement of leptomeninges correlates with 
presence of melanin in leptomeninges. If lesions are suspected follow 
up with serial MRI is recommended. 
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HYPOMELANOSIS OF ITO 
It is the third most frequent neurocutaneous disease exceeded by 
NF1 and TSC. It is a sporadic disease most common on 
chromosomes18, 12, and X. 
 
Clinical Features 
1. Skin: Macular hypopigmented whorls and patches with 
irregular borders and white lines of Blaschko type is the 
common   presenting feature which occur within first 2 years of 
life in 90% of patients. Lesionsdoes not correlate with severity 
of disease. Other types of cutaneous lesions are nevus 
marmorata, angiomatous nevi and Mongolian blue spot.  
2. Neurological features include mental retardation, autism, 
seizure, strabismus and nystagmus. 
3. Other features are dental hamartomatous tumors, scoliosis, 
finger and toe anomalies, corneal opacification and cataracts.  
Brain imaging shows atrophy and hemimegalencephaly (50%), 
cerebellar hypoplasia and agyria, pachygyria
29
. 
 
FABRY’S DISEASE 
(ANGIOKERATOMACORPORIS  DIFFUSUM) 
It is a X-linked recessive lysosomal storage disease resulting 
from the deficiency of α-galactosidase. GAL gene is localized to 
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chromosome Xq22. Sphingolipid accumulation occurs in vascular 
endothelial cells, smooth muscle cells, sweat gland cells, 
macrophages, central neurons, gastrointestinal ganglionic neurons, 
cardiac muscle, astrocytes, meningeal cells and autonomic ganglion 
cells resulting in clinical manifestations. 
 
Clinical Manifestations 
1. May begin as early as 4 years. Mean age of onset is 10 years. 
Skin manifestations include angiokeratoma which are 
hyperkeratotic areas of dilated blood vessels, typically purple-
black in color.  They are most commonly seen over the “swim 
trunk” region. 
2. Neurological manifestations include pain crises (characterised 
by acute, episodic, neurogenic pain triggered by stress, heat, 
fatigue, exercise) and acroparesthesia resulting from small-
fiber peripheral neuropathy
30
. Rarely small-vessel ischemic 
strokes can also occur. 
3. Other features are corneal opacity, progressive renal failure, 
hypertension, myocardial infarction, valvulopathy, 
cardiomyopathy and depression. 
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 Fabry’s disease is diagnosed by low or absent α-galactosidase A 
enzyme level in plasma, serum, leukocytes, or cultured fibroblasts. 
Skin, kidney and conjuctival biopsy are also helpful in the diagnosis. 
 
VON HIPPEL-LINDAU DISEASE 
 It is an autosomal dominant disease characterized by 
hemangioblastomas of central nervous system and retina and renal cell 
carcinomas. Other   associated features are   pheochromocytomas, 
pancreatic isletcell tumors, endolymphatic sac tumors of middle ear, 
neuroendocrine tumors of pancreas and cystadenomas of epididymis 
and broad ligament. VonHippel-Lindau (VHL) gene is located on 
chromosome 3p26-p255. 
 
Diagnostic Criteria
31
 
1. Family history and the finding of a single retinal or Cerebellar 
hemangioblastoma, pheochromocytoma, or renal cell 
carcinoma. 
2. If no definite family history of VHL disease, two retinal or 
cerebellar hemangioblastomas or one hemangioblastoma plus 
one visceral tumor
.
 
Types  
Type I. VHL without pheochromocytoma (most common type) 
Type II. VHL with pheochromocytoma 
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Imaging finding 
Hemangioblastoma are detected by imaging. Common CNS 
sites are cerebellar hemisphere, followed by spinal cord usually 
cervical or thoracic region. 
 
HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) 
Syn: OSLER WEBER RENDU DISEASE 
It is an autosomal dominant disease characterized by 
mucocutaneous telangiectasias in multiple organs. Usually   onset of 
illness occurs before 40 years of age. There are 2 sub types. HHT 1 
and HHT 2. Type 1 is usually associated with pulmonary involvement. 
  
Clinical Manifestations 
1. Mucocutaneous telangiectasias: common locations are nasal 
cavity, oral cavity, lips and fingers. 
2. Neurological manifestations include cerebral abscess, stroke, or 
transient ischemic attack (TIA) due to paradoxical shunting, 
cerebral and spinal arteriovenous malformations, cerebral 
aneurysms, cavernous angiomas and migraine headache
32
. 
 
Criteria for Diagnosis of Hereditary Hemorrhagic Telangiectasia 
1. Epistaxis: recurrent nose bleeds 
2. Telangiectasias: in lips, oral cavity,  fingers, nose 
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3. Visceral lesions: Gastrointestinal telangiectasias, pulmonary 
and hepatic arteriovenous malformations, spinal  and cerebral 
vascular malformations. 
4. Family history of first-degree relative with hereditary 
hemorrhagic telangiectasia 
1. Definite: three criteria are present 
2. Possible: two criteria are present 
3. Unlikely: fewer than two criteria present. 
 Neuro imaging shows flow voids, with or without hemorrhage, 
mass effect, edema, gliosis. GRE is useful in detecting micro-
hemorrhages. 
 
XERODERMA PIGMENTOSUM 
It is an autosomal recessive disorder that presents with extreme 
photosensitivity of skin and eyes and premature cutaneous aging. The 
defect is in the genes involved in nucleotide excision repair 
mechanisms. Higher incidence is reported in Israel, Japan and Egypt.  
 
Clinical Manifestations 
1. Photosensitivity, erythema and blistering starts between 1to2 
years of age in 50% of patients,  by 4 years in 75% of patients 
and by 15 years in 95% of patients.  They may later develop 
basal cell carcinoma
33
. 
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2. Eyes are affected in 80% with the median age of 4 years. 
Telangiectasias, ectropion, entropion and keratitis are the 
common ophthalmic features. 
3. Neurologic manifestations include mental retardation, ataxia, 
spasticity, abnormal ocular motility, sensory neural deafness, 
seizures and axonal neuropathy
34
. Rarely DeSanctis-Cacchione 
syndrome (progressive neurologic degeneration) develops in 
20% of patients. Carcinoma is the most common cause of death 
followed by infection. MRI shows cortical atrophy. 
 
EPIDERMAL NEVUS SYNDROME (Schimmelpenning’s syndrome) 
It May be sporadic or autosomal dominant with the incidence of 
1:1,000 live births. Male and female are equally affected. 
 
Clinical Manifestations 
1. Epidermal nevi 
 They are typically linear, do not cross midline and follow the 
lines of Blaschko. Head and neck are the most common sites of 
occurrence. It can involve anus, mouth and genitalia. 
 
2. Neurological manifestations 
 Occur in 50% of patients. Seizures, mental retardation and 
rarely spastic hemiparesis can occur.  Structural abnormalities include 
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hemiatrophy, hemimegalencephaly, agenesis of corpus callosum and 
hamartoma
35
. 
 
3. Eyelid involvement, choristomas
36
, kyphoscoliosis and enamel 
hypoplasia are the other abnormalities that can occur. 
Neuroimaging shows calcifications and angiography shows 
arteriovenous malformations. 
 
MENKES’ SYNDROME (KINKY HAIR DISEASE) 
It is a X-linked recessive lethal disorder resulting from 
maldistribution of body copper. Responsible gene is MNK gene on 
chromosome Xq13 that encodes for copper-transporting membrane 
ATPase which is expressed in all tissues except liver. Pathological 
features are degeneration of cortical gray matter, with neuronal loss 
and gliosis and loss of Purkinje cells in cerebellum. 
 
Clinical Manifestations 
1. Most common initial symptoms are delayed development and 
seizures. 
2. Hypothermia, hypotonia, hypoglycemia and failure to thrive are 
the symptoms seen in neonates. 
3. Hair becomes colourless and friable. Trichorrhexis nodosa may 
occur. 
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4. Other associated findings are osteoporosis, hydronephrosis and 
blindness. Subdural hematoma and respiratory failure are late 
manifestations. Majority die before the age of 2years due to 
infections and cerebral haemorrhage
37
. 
 
 Diagnosis is by low copper and ceruloplasmin levels. Neonatal 
diagnosis can be made by copper uptake studies in cultured 
fibroblasts. 
MRI shows  diffuse cortical atrophy and impaired myelination. 
 
CEREBROTENDINOUS  XANTHOMATOSIS 
It is an autosomal recessive disorder that affects the brain and 
tendons. The defective gene is located on chromosome 2q33. Impaired 
hepatic conversion of cholesterol to cholic and chenodeoxycholic 
acids leads to accumulation of cholesterol and cholestenol in tissues.  
This results in xanthomatous lesions in the Cerebellum adjacent to 
dentate nucleus, basalganglia, brainstem and spinal cord
38
. 
 
Clinical features 
1. Tendonxanthomas are seldom seen before 20 years. They are 
commonly found over achilles tendon. 
2. Mental retardation, pyramidal and cerebellar signs are the 
neurological manifestations. 
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3. Other features are premature atherosclerosis, osteoporosis, 
repeated fractures, cataracts, chronic diarrhea and pulmonary 
insufficiency. 
4. Early diagnosis and treatment can prevent neurologic 
complications. Presence of two of four clinical hallmarks 
should prompt metabolic screening which may reveal increased 
plasma and bile cholestanol levels and increased urinary bile 
alcohol glucuronides associated with decreased biliary 
concentration of chenodeoxycholic acid. Brain imaging shows 
cerebral and cerebellar atrophy. 
 
INCONTINENTIA PIGMENTI 
(BLOCHSULZBERGER SYNDROME) 
It is a X-linked dominant disorder with mutation of 
NEMO/IKKγ gene located on Xq28. This gene is involved in 
expression of multiple genes protecting cells against apoptosis. 
 
Clinical Manifestations 
1. Skin features:  skin lesions appear at or shortly after birth and 
evolve over time.  Skin manifestation occurs in four stages. 
 
Stages of Incontinentia Pigmenti 
Stage 1: Bullous stage (birth to first 8 weeks of life) 
Stage 2: Verrucous stage (arises as stage 1 begins to resolve) 
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Stage 3: Hyper pigmentation stage (6 months into adulthood) 
Stage 4: Atrophic stage (does not occur in all patients).   
 
2. Neurologic features are mental retardation (15%), seizures, infantile 
spasms (13%) and microcephaly (5%)
39
.
 
 
3.20% may have severe vision abnormalities like retinal or ocular 
lesions vitreous hemorrhage, retinal detachment, strabismus and 
conjunctival pigmentation. 
 
4. Absent teeth and poor enamel quality, skull deformities, scoliosis, 
clubfoot and syndactyly are the other features. 
Diffuse atrophy, hypoplasia of corpus callosum and ventricular 
dilatation are the imaging findings that may be present. 
 
ENCEPHALOCRANIOCUTANEOUS SYNDROME 
(HEBERLAND SYNDROME) 
It is a sporadic disorder characterized by neurological, skin and 
eye abnormalities. It usually presents in infancy to childhood. Skin 
features are lipoma, polyps, alopecia and nail changes. Neurological 
manifestations are mental retardation, seizures, macrocephaly, 
hemiplegia, quadriplegia and spastic paraplegia. Eye features are 
chorioretinal abnormalities and micropthalmos. Facial dysmorphism is 
not uncommon. Unilateral cerebral hemispheric atrophy ipsilateral to 
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scalp lipoma is noted. MRI detects intracranial (1C) lipomas and 
spinal lipomas mostly at cervicothoracic than lumbar region. 
Hemispheric atrophy, ventriculomegaly due to volume loss, 
leptomeningeal lipomatosis and polymicrogyria are the other features 
detected by imaging
40
. 
 
PROGRESSIVE FACIAL HEMIATROPHY 
(PARRY-ROMBERG SYNDROME) 
 Typically presents in first or second decade. Female male ratio 
is1.5:1. Cause is unknown. Proposed theories include infection, 
trigeminal neuritis, scleroderma and cervical sympathetic loss. 
Sometimes it may begin after trauma. 
  
Clinical Manifestations 
 Progressive hemifacial atrophy in the distribution of cranial 
nerve V and linear scleroderma of forehead called en coup DeSabre 
are the classical findings. Central nervous system features include 
trigeminal neuralgia, migraine, seizures, hemianaesthesia, hemianopia 
and ipsilateral Horner syndrome. Loss of hair and vitiligo are 
associated features
41
. MRI shows ipsilateral corpus callosum 
infarction, sub cortical white matter changes, ipsilateral 
leptomeningeal enhancement and calcification and ipsilateral 
atrophy
42
. 
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Ehlers-Danlos Syndrome Type IV 
It is an autosomal dominant disorder that occurs due to mutation 
ofCOL3A1 gene on chromosome 2 which encodes for type III 
procollagen synthesis.   Deficiency of collagen type III, which is a 
major component of distensible tissues including arteries and veins, 
results in fragmentation of arterial internal elastic membrane, fibrosis 
of arterial wall and microscopic ruptures between media and 
adventitia. 
 
Clinical presentation 
1.  Easy bruising, thin translucent skin, thin nose, hollow cheeks, 
reduced adipose tissue and skin hyperextensibility. 
2. Small joint hypermobility and  tendon rupture 
3. spontaneous pneumothorax and  early varicose veins . 
4. Neurological features include optic atrophy, sensory neural 
hearing loss, cerebellar ataxia and neuropathy
43
.  
It is diagnosed by fibroblast culture to detect procollagen III 
molecules. Neuro imaging shows intra cranial aneurysm and 
cerebral atrophy. 
 
Cerebrovascular Complications  
1. Carotid-cavernous fistula 
2. Spontaneous arterial dissection 
3. Intracranial aneurysm formation 
40 
 
MATERIALS AND METHODS 
 
The study was done at Madras institute of Neurology, Rajiv 
Gandhi Government General Hospital, Chennai for a period of 24 
months, from January 2011 to December 2012.  Hundred patients with 
symptoms and signs pertaining to neurocutaneous syndromes were 
included in the study. 
 
Basic demographic data like age, sex and educational 
qualification were noted.  A detailed history was elicited including 
history of present and past illness; family history and consanguinity. 
General examination and a detailed systemic examination were done 
in all patients to look for any associated systemic abnormalities. 
 
A detailed history pertaining to neurological symptoms was 
elicited and a thorough examination of the central nervous system was 
done in all patients.  Assessment of IQ was done.  The cutaneous 
findings were noted and a dermatologist opinion was obtained.  Eye 
examination, ear and dental examinations were done and opinion 
obtained in relevant cases. 
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The following investigations were done in all patients: 
1. Complete hemogram 
2. Liver function test 
3. Renal function test 
4. Blood Sugar 
5. Serum Lipid Profile 
6. X Ray 
7. ECG 
8. Ultrasound abdomen 
9. EEG 
10. CT/MRI 
 
 Nerve conduction study was done in relevant cases. The 
radiological findings were noted and analyzed in all patients.  
 The data thus obtained was compiled, tabulated and analyzed. 
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OBSERVATION AND RESULTS 
 
 Total number of new patients who attended the neurology OPD 
at Government General Hospital during the period between January 
2011 to December 2012 were 32,168.  Among them 100 patients 
(0.3%) were identified with symptoms and signs pertaining to 
neurocutaneous disorders.  The various neurocutaneous disorders that 
were observed in our study are as follows in order of frequency.  
 
1. Neurofibromatosis     - 66  
2. Tuberous sclerosis                - 18  
3.  Sturge Weber syndrome                        -         4 
4. Ataxia telangiectasia    -         3 
5. Epidermal naevus syndrome   - 2  
6. Giant congenital melanocytic naevus  - 2  
7. Xeroderma pigmentosum    - 1  
8.  EhlerDanlos syndrome type IV  - 1 
9. Hypomelanosis of Ito    - 1 
10. Incontinentia Pigmenti    - 1 
11. Hereditary hemifacial atrophy   - 1 
 
In our study the most common neurocutaneous disorder 
observed was Neurofibromatosis followed by Tuberous sclerosis and 
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Sturge Weber syndrome. Seizures were the most common 
neurological manifestation noted in these disorders followed by 
learning disability and mental retardation. 
 
 
Figure: 1 
 
NEUROFIBROMATOSIS (NF) 
 66 cases of neurofibromatosis were observed in our study. Of 
these, 59 cases (89.3%) had NFI, 3 cases (4.5%) had NFII, 2 cases 
(3.03%) had NF V and 2 cases (3.03%) had NF VI. 
66
18
4
3
2
2
1 1
1
1 1
Spectrum of neurocutaneous syndrome
Neurofibromatosis 
Tuberous sclerosis 
Sturge Weber syndrome                             
Ataxia telengectasia
Epidermal naevus syndrome5
Giant congenital melanocytic 
naevus
Xeroderma pigmentosum
EhlerDanlos syndrome
Hypomelanosis of Ito
Incontinentia  Pigmenti
44 
 
TABLE 1 
Types of neurofibromatosis observed in our study 
 
Type of 
Neurofibromatosis 
No. of cases % 
NF I 59 89.3 
NF II 3 4.5 
NF V 2 3 
NF VI 2 3 
 
Age and sex distribution: The age group of patients with neurofibroma 
ranged from 1 to 55 years with the mean age of 28 years. 
 
 
Figure 2 
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TABLE-2 
The Age and Sex Distribution among Patients with NF (N=66) 
 
Age No. of Cases M F 
< 10 yrs 3 2 1 
11 – 20 yrs 25 14 11 
21 – 30 yrs 19 10 9 
31 – 40 yrs 13 8 5 
41 – 50 yrs 3 1 2 
Above 50 yrs 3 2 1 
Total 66 37 29 
 
Family History: Neurofibromatosis was observed among the family 
members in 18 cases (27.2%).  
 
Cutaneous manifestations: 61 patients (92.4%) had mollusca fibrosa 
(neurofibroma) lesions. Plexiform neurofibromatosis was observed in 
3 patients (5%) of which one patient presented with plexiform 
neurofibromatosis in the lower limb.  Café au lait macules were seen 
in 57 patients (86%). Freckling in the palms, axillary and inguinal 
regions was noted in 52 patients (78%). One male patient had 
excessive freckling over the face. It was noted from the history that 
café au lait macules were the earliest cutaneous marker to appear and 
the number of neufibroma lesions increased at puberty.  
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Neurological Manifestations: 13 patients (19.6%) with NFI had 
neurological symptoms of which 3 patients (5%) presented with 
seizures. Two patients had generalised tonic clonic seizures and one 
had right focal seizures with secondary generalisation.  Five patients 
(7.5%) had mental retardation, 6 patients (9%) had learning 
difficulties, 2 patients (3%) had quadriparesis and 1 patient (1.5%) had 
paraparesis.   One patient (1.5%) had optic nerve glioma and presented 
with loss of vision. 
 
All the three NF2 patients presented with hearing loss. One case 
of NF2 with bilateral acoustic schwannoma presented with features of 
raised intracranial tension. 
 
TABLE - 3 
Neurological manifestation in neurofibromatosis 
Neurological manifestation No. of Patients 
Seizures  3 
Learning disability 6 
Mental retardation 5 
Quadriparesis 2 
Paraparesis 1 
Vision loss 1 
Sensory neural deafness (NF 2) 3 
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Figure: 3 
 
EEG findings:  Among the 3 patients who presented with seizures, 2 
patients showed epileptiform activity in EEG. 
 
Ophthalmic manifestations: 49(74%) patients had lisch nodules in 
both eyes. 
 
Bony abnormalities: 9 patients (13.6%) had bony abnormalities of 
which 5 had kyphoscoliosis (7.5%), 2 had facial asymmetry (3%) and 
2 had pseudoarthrosis of tibia (3%). 
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TABLE-4 
Systemic manifestations observed in patients with 
neurofibromatosis 
 
Systemic Manifestations No. of Patients 
Bony abnormalities 
Kyphoscoliosis 5 
Facial asymmetry  2 
Pseudoarthrosis of tibia 2 
Ophthalmic Manifestations  
Lisch  nodules 49 
 
Imaging studies 
Radiological abnormalities were present in 21 patients (31.8%).  
MRI T2 weighted images showed small multiple high signal intensity 
areas called unidentified bright objects (UBOs) in 12 patients (20%) 
with NF1. One patient had optic nerve glioma and none of the patients 
had parenchymal glioma.  Hamartoma in thalamus and parietal cortex 
were present in two patients. One patient who presented with 
quadriparesis showed spinal cord intra dural extramedullary 
compression at cervical level.  The other patient with quadriparesis 
showed multiple level compressions. Imaging of another patient who 
presented with paraparesis showed compression at thoracic level with 
lateral extension through the nerve root forming dumb bell tumour. 
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TABLE -5 
Neuro imaging in Neurofibromatosis 
 
S. No 
Type of 
neurofibroma 
Imaging finding No. of patients 
1 NF1 UBO 12 
2 NF1 Optic nerve glioma 1 
3 NF1 Hamartoma 2 
4 NF1 Spinal cord compression 3 
5 NF2 Acoustic neuroma 3 
 
 MRI in all the 3 patients with NF2 showed acoustic neuroma.  
One patient had multiple schwannoma, meningioma and ependymoma 
(Multiple inherited Schwannoma, Meningioma and Ependymoma - 
MISME syndrome). 
 
Figure: 4 
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TUBEROUS SCLEROSIS (TSC) 
Eighteen patients were diagnosed with tuberous sclerosis of 
whom 6 were male and 12 were female. The age of these patients 
ranged from 4yearsto 38 years – the mean age being 21 years. 
 
TABLE -6 
The age and sex distribution in tuberous sclerosis complex (n=18) 
  
Age No. of Case M F 
Less than 10 yrs 3 1 2 
11 – 20 yrs 9 3 6 
21 – 30 yrs 4 1 3 
31 – 40 yrs 2 1 1 
TOTAL 18 6 12 
 
Family history: 
 Two families were documented with manifestations of tuberous 
sclerosis in three generations.  
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TABLE - 7 
Cutaneous findings in patients with tuberous sclerosis 
 
Cutaneous Marker No of Patients (Total = 18) 
Angio fibroma 18(100%) 
Ash leaf macules 16(85%) 
Shagreen patch 12(75%) 
Molluscum  pendulum 3(35%) 
Forehead plaque 4(20%) 
Koenen’stumour 5(28%) 
CALM 3(16%) 
Confetti macules 2(11%) 
Gingival fibroma 1(5%) 
Enamel pits 10(60%) 
 
 Angio fibroma was the most common cutaneous finding 
followed by Ash leaf macules and Shagreen patch. Shagreen patch 
was frequently seen in the lumbosacral region. 
 
Neurological manifestations: 
 
Figure: 6 
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Seizure was the most common neurological symptom noted in 
patients with tuberous sclerosis.  Fifteen patients (83.3%) had seizures 
of which 9 patients had generalized tonic clonic seizures, 3 patients 
had focal seizures with secondary generalization and 3 patients had 
multiple seizure type.  Of the fifteen patients with seizures 12 patients 
(80%) had intractable seizures.  Eight patients (44.4%) had mental 
retardation and 2 patients (11%) had history of delayed mile stones. 
Learning disability was noted in 9(50%) patients. Microcephaly was 
noted in 2 patients (11%). 
 
TABLE - 8 
Neurological manifestations in tuberous sclerosis 
 
S. No Symptom No. of patients  
1. Seizures 15(83.3% 
2. Learning disability 9(50%) 
3. Mental retardation 8(44.4%) 
4. Delayed mile stones 2(11%) 
5. Microcephaly 2(11%) 
 
EEG findings:  Abnormal findings in EEG were present in 6 patients 
of whom 4 patients showed spike and slow waves, and 2 patients 
showed bilateral diffuse slow waves. 
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Imaging studies: 
 Neuroimaging revealed abnormality in 7 patients (38%). 
Subependymal nodules were noted on the walls of lateral ventricle in 
3 patients (16.6%). Cortical tubers were noted in 3 patients (16.6%), 
all in frontal lobe which were not enhancing with contrast.  Sub 
ependymal giant cell astrocytoma (SEGA) was present in one patient 
(5.5%). 
 
 
Figure: 7 
 
Other findings:   
 Ultrasonogram of abdomen revealed renal angiomyolipoma in 
two patients. Echocardiogram of one patient showed rhabdomyoma of 
heart. 
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STURGE WEBER SYNDROME 
Four patients were identified to have Sturge Weber syndrome of 
whom three were female and one was male. All the patients denied 
family history or consanguinity. All the four patients presented with 
portwine stain over the face.  Three patients had unilateral portwine 
stain while one patient had bilateral portwine stain.   In addition to 
portwine stain, conjunctival congestion, prominent blood vessels over 
the upper and lower eyelids and glaucoma were also noted in the 
patient with bilateral portwine stain.  
 
TABLE - 9 
Clinical spectrum in Sturge Weber syndrome 
 
No of patients 4 
Sex Distribution M – 1, F – 3 
Portwine stain 3 – Unilateral; 1 – Bilateral 
Other features  Conjunctival congestion, prominent 
blood vessels over the upper & lower 
eyelids and glaucoma 
Neurological Manifestation Seizures 
Neuroimaging  Calcification over the parietooccipital 
region  with atrophy 
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Among the four patients, three patients presented with seizures 
and their EEG showed focal epileptiform spikes.  One female patient 
presented at the age of thirteen years with low IQ, intractable seizures, 
and squint. One patient presented at the age of 60 years with seizures 
and haemangioma of lower lip. 
 
Imaging of these patients showed serpiginous calcification and 
atrophy over the parietooccipital region with. Gradient echo showed 
blooming. 
 
ATAXIA TELANGIECTASIA 
 
TABLE - 10 
Clinical Spectrum in Ataxia telangiectasia 
 
No of patients 3 
Sex Distribution M – 1, F – 2 
Telangiectasia All patients (seen at conjunctiva) 
Neurological Manifestation Ataxia in all 3 patients. 
One patient had oculomotor apraxia, 
peripheral neuropathy, mental 
retardation and seizures also. 
Neuroimaging  Cerebellar atrophy 
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Three patients were diagnosed with ataxia telangiectasia.  Two 
patients, an eight years old female child and a thirteen years old male 
child were siblings from the same family.  All the three patients had 
telangiectasia in the conjunctiva. One patient had telangiectasia over 
the nose also. Truncal ataxia, nystagmus, dysarthria and recurrent 
respiratory infections were noted in all the three patients.  All had 
absent deep tendon reflex.  In addition to the above findings, a thirteen 
years old patient presented with low IQ, generalised tonic clonic 
seizures, sensory neuropathy, oculomotor apraxia, severe limb and 
truncal ataxia. He also had impaired GTT and epileptiform activity in 
EEG. MRI of this patient showed severe atrophy of cerebellar 
hemispheres and vermis. MRI of the other two patients showed only 
vermian atrophy. 
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Other rare Neurocutaneous Syndromes 
 Few uncommon neurocutaneous syndromes observed in our 
study and their clinical features and imaging findings are tabulated 
(Table 11).  
  
TABLE - 11 
Other rare Neurocutaneous Syndromes 
 
5555 No. Of 
patients 
Neurological 
Manifestion 
Cutaneous 
Manifestion 
Imaging 
Epidermal naevus 
syndrome 
2 Seizure – 1 
Headache -1 
Epidermal Naevus Normal 
Giant congenital 
melanocytic 
naevus 
2 Seizure – 1 
Headache -1 
Giant Naevus Normal 
Xeroderma 
Pigmentosum 
1 Optic atrophy 
Deafness, Mental 
retardation 
Photophobia, 
Freckles, xerosis 
Diffuse cortical 
atrophy 
EhlerDanlos 
syndrome 
1 Optic atrophy 
Deafness 
Hyperextensible 
Skin and joints 
Normal 
Hypomelanosis 
of Ito 
1 Seizure  
Mental retardation 
Hypopigmentation 
along Blaschkow 
lines 
Pachygyria 
Incontinentia 
Pigmenti 
1 Seizure  
 
Marble cake 
pigmentation 
Cortical 
atrophy 
Hereditary 
hemifacial 
atrophy 
1 Seizure  
 
Atrophy of face Ipsilateral 
Hemispheric 
atrophy 
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TABLE 12 
Summary of neurological manifestations in Neurocutaneous 
Syndrome 
 
Neurocutaneous Syndromes Neurological manifestations 
Seizure Learning 
Disability 
Mental 
Retardation 
Ataxia Weakness Deafness Blindness 
Neurofibromatosis 
(n - 66) 
3 6 5 - 3 3 1 
Tuberous sclerosis 
(n - 18) 
15 9 8 - - - - 
Sturge Weber syndrome 
(n - 4) 
3 1 1 - - - - 
Ataxia telengectasia 
(n - 3) 
1 1 1 3 1 - - 
Epidermal naevus syndrome 
(n - 2) 
1 - - - - - - 
Giant congenital melanocytic 
naevus 
(n - 2) 
1 - - - - - - 
Xeroderma pigmentosum 
(n - 1) 
- 1 1 - - 1 1 
 
EhlerDanlos syndrome 
(n - 1) 
- - - - - 1 1 
Hypomelanosis of Ito 
(n - 1) 
1 1 1 - - - - 
Incontinentia Pigmenti 
(n – 1) 
1 - - - - - - 
Hereditary hemifacial atrophy 
(n - 1) 
1 - - - - - - 
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DISCUSSION 
  
Neurocutaneous disorders are a group of genetic disorders 
characterized by congenital dysplastic abnormalities involving the 
skin and the nervous system.  Skin lesions usually appear at an early 
age while neurological features usually present at a later age.  Neuro 
imaging studies help to assess the extent of neurological involvement 
and to predict the prognosis.  With this background we studied 100 
cases of neurocutaneous disorders and analyzed the neurological 
manifestations and the radiological findings. 
 
The most common neurocutaneous disorder observed in our 
study was neurofibromatosis (66%) followed by tuberous sclerosis 
(18%) and Sturge Weber syndrome (4%). Other rare neurocutaneous 
disorders like ataxia telengectasia (3%), Giant congenital melanocytic 
naevi (2%), Epidermal naevus syndrome (2%), Xeroderma 
pigmentosum (1%), Incontinentia Pigmenti (1%), Hypomelanosis of 
Ito (1%), Ehler Danlos Syndrome (1%) and Hereditary Hemifacial 
atrophy (1%) were also observed. 
 
Seizures, learning disability and mental retardation were the 
most common neurological symptoms noted in our study. The most 
common neurocutaneous disorder that presented with seizures was 
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Tuberous Sclerosis (83.3%) followed by Sturge Weber Syndrome 
(75%).  Seizures were also noted with high frequency in other less 
common disorders like Ataxia telengectasia, Giant congenital 
melanocytic naevi, Epidermal naevus syndrome, Hypomelanosis of 
Ito, Heritary hemifacial atrophy and Incontinentia pigmenti also. 
Neurofibromatosis was the most common disorder observed in our 
study but the prevalence of seizures in neurofibromatosis was low. 
These findings coincide with the study by Prakash Kotagal et al
44
. 
 
NEUROFIBROMATOSIS  
 Neurofibromatosis type 1 was the most common type of 
neurofibromatosis noted in our study and accounts for 89.3% of 
neurofibromatosis cases. This is closer to the incidence noted in the 
series of Husan SM et al
45
where they have documented 90% 
incidence.  The incidence of NF1 was higher in our study compared to 
the study by Sandipandhar et al
46
in which the incidence of NF1 was 
only 60%.  The incidence of NF2 in our study was 4.5%. Few cases of 
rare NF variants were also observed. Two cases (3%) each of NF V 
and NF VI were noted in our study.   Crowe FW et al
47
 considered NF 
VI to be a rare variant. 
In our study male sex (56%) was predominantly affected which 
is in contrast with the study by Jennifer R. Kam et al
48
who showed 
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equal male female ratio. The most frequent age group affected was            
11-20 years. 
 
In our study, Mollusca fibrosa (92.4%) was the most common 
cutaneous finding followed by Cafe au lait macules (86%) and 
freckling(78%).Increase in number of lesions at puberty which was 
noted in our study was also noted by Friedmann JM Riccardi et al
49
. 
Café u lait macules were the earliest marker to occur in  our study.  
This coincides with the study by Crow and Schull et al
50,51
. The 
incidence of café u lait macules was higher in our study compared to 
the study by Neil Gold Berg et al
52
 in which Café au lait macules were 
noted in 69% of cases. Plexiform neurofibromatosis was observed in 
5% of cases in our study as opposed to the 30% incidence noted in the 
Wallenstein et al study
53
. Axillary freckling was noted in 78% of cases 
which was closer to the incidence of 70% noted  in the study by 
Crowe FW et al
51
 . 
 
Lisch nodules were observed in 74% of patients as opposed   to  
Fliieler et al study which showed 95% occurence.
54 
Kyphoscoliosis  
was noted  in 7.5% of patients which was higher than the 2% 
incidence noted in the study by Riccardi VM et al
55
.  Pseudoarthrosis 
of tibia was seen in 3% of cases as opposed to AJ Kanwar et al 
56
 
study which showed 13% incidence. 
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Neurological manifestations were noted in 19.6% of 
neurofibromatosis cases which coincides with the study by Kaufmann 
et al
57
. Among the neurological manifestations seizure was noted in 
5% of cases while 10% of cases were found to have seizures in the 
study by Cramer et al
58
. Mental retardation occurred in 7.5% of cases 
as opposed to the study of Allanson JE et al
59.
.Learning difficulty was 
noted in 9% of cases which was lesser than the 30 – 70% incidence in 
the North Kn et al study
60
.Compressive myelopathy occurred in 5% of 
cases in our study as opposed to the study of Leonard et al
61
 in which 
1% had compressive myelopathy. 
 
In our study 100% of NF2 patients presented with acoustic 
neuroma which was much higher than the incidence of 30% noted in 
the study by Loveneret al
62
. 
 
Radiological findings were present in 31.8% of  
Neurofibromatosis  patients.  This was closer to that of Hsiesh HY et 
al study
63 
in which radiological findings were present in 35% of cases. 
The most common finding in MRI T2 weighted imaging was 
Unidentified bright objects (UBO) noted in 20% of cases which 
coincides with the observation of DeBella et al
64
. Optic nerve glioma 
was present in 1.5% of patients. These findings coincide with the 
study by Szudek J et al
65
. In our study imaging showed spinal cord 
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compression in 5% of cases as opposed to the study by J R Leonard et 
al
61
 which noted spinal cord root compression in 1% of cases.
 
 
.
 
TUBEROUS SCLEROSIS 
Tuberous Sclerosis (18%) was the second most common 
neurocutaneous disorder observed in our study next to neuro 
fibromatosis. The common age group of presentation was 10-20 years. 
The mean age of presentation in our study was 21 years while G. 
Raghu Rama Rao et al
66 
study noted a mean age of 16 years. In our 
study, family history was present in 10% of patients.  This was lesser 
compared to H. Northrup et al
67
 study who observed positive family 
history in 30% of their cases. Our study noted a female preponderance 
as opposed to Rabindrnath Nambi et al
68
study which showed an equal 
sex incidence. 
 
 Angiofibroma of the face was the most common cutaneous 
finding which was present in all patients in our study.  This was 
consistent with Gomez MR et al
69
study which showed 95% incidence. 
Ash leaf macule was observed in 85% of cases as opposed to 100% in 
Jimbow K et al
 70
study. Shagreen patch was  found in lumbosacral 
region frequently which is consistent with the report of Tsao H et 
al.
71.
Shagreen patch was observed in 75%  of cases as opposed to 50% 
reported by Harris stith et al
72 . 
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 Koenens tumour was noted in 28% of cases which was higher 
than the 15% incidence noted by Joswiak et al
31
study. Among the 
neurological manifestations,   seizures were found in 83%of cases in 
contrast to the Satish chandra et al
73
 study where they have observed 
seizures in only 53% of their cases.  Seizures were refractory to 
treatment in most of the cases. In our study we noted mental 
retardation in 44.4% of cases which was closer to the 40% incidence 
noted by Raghu Rama Rao et al.
66.
 Microcephaly with seizures was 
noted in 11% of cases in our study and this was consistent with 
Chandra PS et al
74
 study. 
 
Neuroimaging : 
 Subependymal nodules were noted in 16.6% of cases as 
opposed to Curatolo p et al
75 
study which noted 50% incidence. 
Cortical tuber was noted in 16.6% in contrast to Rupa Radhakrishnan 
et al
76
study where they noted 80% incidence. Sub ependymal giant 
cell astrocytoma was noted in only 5.5% of patients in our study in 
contrast to 26% of patients in Morimoto et al series
77
. Renal 
angiomyolipoma was detected in 10% in contrast to 60% reported in 
many literatures. 
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STURGE WEBER SYNDROME  
 In our study, 4% of patients were diagnosed to have Sturge 
Weber syndrome with unilateral port wine stain in 75% of cases and 
bilateral portwine stain in 25% of cases.  This coincides with Tallman 
B et al study
78
.  There was a female preponderance.  75% of patients 
presented with seizures which was similar to the findings of Sujansky 
E et al
79 
study where seizures was observed in 75 to 90% of their 
cases. The seizures were refractory to medications as shown in 
Tallman B et al study
78
. EEG showed focal epileptiform spike 
discharges which coincides with the Brennei RP et alstudy
80
.In neuro 
imaging Leptomeningeal angiomatosis, the hall mark of sturge weber 
syndrome was observed in 75% of our patients which is consistent 
with Griffith et al study
81
.   
 
ATAXIA TELANGIECTASIA   
In our study 3% of patients were found to have ataxia 
telangiectasia. 100% presented with oculcutaneous telangiectasias and 
66% had a positive family history.  These findings coincide with 
Sedwick R etalstudy
82
.All patients had ataxia, dysarthria and recurrent 
respiratory infections which were similar to the findings in  Boder E et 
al study
83
. In neuro imaging 100% had  vermian atrophy  which 
coincides with the study by Ottonello C et al
84
.  One patient showed 
sensory neuropathy and impaired GTT as described in literatures. 
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EPIDERMAL NAEVUS SYNDROME  
 2% of patients in our study had epidermal naevus syndrome. 
One patient had migraine headache. One patient (50%) had seizures 
which correlated with the study of Gurecki PJ et al
85
. None of our 
patients had other neurological abnormalities like facial hemiatrophy, 
mental retardation and neuronal migration disorder as shown in Rizzo 
R et al study.
86
 Neuro imaging studies of these patients were normal.  
 
GIANT CONGENITAL MELANOCYTIC NAEVUS 
 In our study 2% of patients presented with giant congenital 
melanocytic naevus. Hypertrichosis was seen in 100% of the cases 
which is consistent with that described in literature
87
.  One patient had 
associated seizures and café- u-lait macule in accordance with the 
study of Zvulunova et al
88
. Another patient had migraine. Both the 
patients had normal neuro imaging studies as opposed to the study by 
Chien JC et al
 89
which showed leptomeningeal thickening and atrophy. 
 
XERODERMA PIGMENTOSUM  
  In our study one female patient had Xeroderma Pigmentosum. 
Photophobia and freckles were the common presentations. Conjuctival 
pigmentation, congestion and loss of vision were present.  These 
findings   coincide with that of AK Dubey et al study
90
. Mild cognitive 
impairement was present and neuro imaging of this patient revealed 
diffuse cortical atrophy. 
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EHLER DANLOS SYNDROME TYPE IV 
We noted one patient with EhlerDanlos syndrome type IV. 
Hyper extensibility of all joints, easy bruising, thin translucent skin, 
hollow cheeks and reduced adipose tissue over the face were the 
clinical findings in the patient. Clinical examination revealed bilateral 
optic atophy with hearing loss.  These findings were noted in the AB 
Tally et al study
91
also. 
 
HYPOMELANOSIS OF ITO 
In our study we noted a case of Hypomelanosis of Ito with 
delayed motor and language milestones, learning disability and 
seizures.  Whorled linear hypopigmented lesions were present along 
Blaschko lines over face, trunk and upper limb.  These findings were 
noted in Pescual et al series
92 
also. Neuroimaging showed diffuse 
cerebral atrophy and pachygyria which coincides with the study of 
steiner et al
93
. 
 
INCONTINENTIA PIGMENTI 
A ten months old female baby with history of blistering in the 
neonatal period was diagnosed to have incontinentia pigmenti.  The 
baby had brownish hyperpigmentation over the axilla and groin with a 
marble cake appearance.  The baby presented with seizures.  All these 
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findings coincide with the study of Smal Hadji-Rabia et al
94
. 
Neuroimaging showed diffuse cortical atrophy. 
 
PROGRESSIVE FACIAL HEMIATROPHY 
(PARRY-ROMBERG SYNDROME) 
In our study we noted one patient with Parry Romberg 
syndrome.  His unpleasing facial appearance with bone and soft tissue 
atrophy correlates with the findings of the study by Stone et al
95
. 
Neuroimaging showed ipsilateral hemispheric atrophy which 
coincides with the findings of Corry et al
96
. 
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CONCLUSION 
 
1. The most common Neurocutaneous syndrome observed in our 
study was Neurofibromatosis (66%) followed by Tuberous 
sclerosis (18%). 
2. The most common neurological manifestation noted in our 
study was seizure. 
3. Among the neurofibromatosis, NF I accounted for the 
maximum number of cases.  Rare variants like NF5 and NF6 
were also observed. 
4. Most common cutaneous marker in our series was 
neurofibroma. 
5. Learning disability, seizures, mental retardation and 
quadriparesis were the common neurological manifestations 
observed in neurofibromatosis. 
6. The most common symptomatology in tuberous sclerosis was 
adenoma sebaceum. Intractable seizures was the most common 
neurological feature. 
7. Among the imaging findings, unidentified bright objects (UBO) 
were the most common MRI finding in NF 1 and Cortical tuber 
and sub ependymal nodules were the common imaging findings 
in tuberous sclerosis.  
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8. Sturge Weber syndrome (4%) presented with portwine stain and 
intractable seizures.  Parietooccipital calcification and cortical 
atrophy were seen in neuro imaging. 
9. Other rare neurocutaneous syndromes observed in our study 
were Ataxia Telangiectasia, Epidermal naevus syndrome, 
Ehlers Danlos Syndrome type IV, Parry Romberg syndrome, 
Xeroderma pigmentosum, Incontinentia pigmenti, Hypo- 
melanosis of Ito and Congenital melanocytic naevus. 
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ABBREVIATIONS 
 
TSC     :  TUBEROUS SCLEROSIS 
NF       :  NEUROFIBROMATSIS 
MRI   :  MAGNETIC RESONANACE IMAGING 
CT       :  COMPUTED TOMOGRAPHY 
MRS    :  MAGNETIC RESONANCE SPECTROSCOPY 
NAA    :  N- ACETYL ASPARTATE 
GRE    :  GRADIENT ECHO 
EEG     :  ELECTRO ENCHEPHALOGRAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROFORMA 
Serial No:        OP No.: 
 
Name:        Address: 
 
Age: 
Sex: 
Occupation: 
If Child, informant: 
Complaints: 
H/o Presenting Illness: 
Onset: 
Duration of skin lesions: 
Site of initial lesion: 
Size of the lesion: 
Number: 
Progression – Evolution: 
Sites affected: 
H/o pain over the lesion: 
H/o photosensitivity: 
H/o Blisters: 
H/o Dry Skin: 
H/o Pigmentary disturbance: 
H/o Alopecia: 
H/o Loss of nail: 
H/o Convulsions: 
H/o Headache: 
H/o Milestones development: 
H/o Mental retardation: 
H/o Neuropsychiatry manifestation: 
H/o Self mutilation: 
H/o Visual disturbance: 
H/o Photophobia: 
H/o Night blindness: 
H/o Hearing impairment: 
H/o Hoarseness of voice: 
H/o Dyspnoea: 
H/o Gynaecomastia : 
H/o Sexual development: 
H/o Muscle weakness: 
H/o Growth retardation: 
H/o Bone involvement: 
H/o Teeth anomalies: 
H/o Urinary symptoms; 
H/o Nausea / Vomiting: 
H/o Abdominal pain: 
H/o Haematemesis: 
H/o Constipation / diarrhea: 
H/o Loss of appetite: 
Past History: 
Treatment History: 
Personal History: 
Family History: 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENERAL EXAMINATION: 
Built: 
Nourishment: 
Orientation: 
Pallor: 
Clubbing: 
Cyanosis: 
Jaundice: 
Pedal edema: 
Lymhadenopathy: 
Pulse: 
BP: 
 
SYSTEMIC EXAMINATION 
CNS: 
Higher mental functions: 
Cranial nerves examination: 
Spino motor system examination: 
Bulk:    Tone 
 
Power   Reflex 
 
Gait: 
Sensory system examination: 
Cerebellum examination: 
Extra pyramidal system: 
Autonomic nervous system: 
Spine and cranium: 
 
OTHER SYSTEM EXAMINATION: 
CVS: 
RS: 
ABDOMEN: 
 
DERMATOLOGICAL EXAMINATION: 
Morphology: 
Number: 
Site: 
Size: 
Distribution: 
Shape: 
Colour: 
Tenderness: 
 
Consistency: 
Compressibility: 
Surface: 
 
Lesions Like: 
1. Neurofibroma 
2. Café au lait spots 
3. Freckles 
4. Lentigens 
5. Angiofibroma 
6. Shagreen patch 
7. Ash leaf macule 
8. Hypopigmented macules 
9. Naevi 
10. Palmar pits 
11. White forelock 
12. Synophrys 
 
 
 
 
 
INVESTIGATIONS 
Complete haemogram 
Blood sugar Lipid profile 
LFT 
RFT 
Xray skull 
USG ABDOMEN 
NCS 
EEG 
CT Scan brain 
MRI Brain 
 
OPINIONS: 
Dermatology opinion 
Psychiatrist opinion 
Neuro surgeon opinion 
Opthalmologist opinion 
Cardiologist opinion 
 
DIAGNOSIS: 
 
 
PATIENT CONSENT FORM 
 
Study Details : Clinical and Radiological features in Neuro Cutaneous 
Syndromes 
Study Centre : Rajiv Gandhi Government General Hospital, Madras 
Medical College, Chennai - 600 003. 
Patient may check () these boxes: 
 I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and doubts have 
been answered to my complete satisfaction. 
 I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal rights being 
affected. 
 I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulartory authorities will not 
need my permission to look at my health records, both in respect of current study 
and any further research that may be conducted in relation to it, even if I withdraw 
from the study I agree to this access. However, I understand that my identity will 
not be revealed in any information released to third parties or published, unless as 
required under the law. I agree not to restrict the use of any data or results that 
arise from this study. 
 I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my health 
or well being or any unexpected or unusual symptoms. 
 I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological tests. 
 I hereby consent to participate in this study. 
 
 
 
Signature / Thumb impression:  
 
Patient Name and Address:   Place:   Date: 
 
Signature of Investigator: 
 
 
Study Investigator’s Name:    Place:   Date: 
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UBO ONG 
SPINAL  
TUMOUR 
ACOUSTIC 
NEUROMA 
HAMAR
TOMA 
1 28 M 1 2 1 1 1 1 1 1 2 2 2 1 1 AB N P A A A A 
2 18 M 1 1 1 1 2 1 1 1 2 2 2 1 2 AB N P A A A A 
3 13 F 1 1 1 1 2 2 1 1 2 2 2 1 2 N N P A A A A 
4 51 M 2 1 1 1 2 2 2 2 1 2 2 1 1 N N A A P A A 
5 48 M 2 1 1 1 2 2 2 2 1 2 2 1 1 N N A A P A A 
6 53 F 2 1 1 1 2 2 2 2 1 2 2 1 1 N N A A P A A 
7 22 F 1 2 2 2 2 2 2 2 2 1 1 2 2 N AB A A A P A 
8 26 F 1 2 2 2 2 2 2 2 2 2 1 2 2 N AB A A A P A 
9 31 M 1 2 2 2 2 2 2 2 2 2 1 2 2 N AB A A A P A 
10 54 M 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A P A A A 
11 7 M 1 1 1 1 2 2 2 2 2 2 2 1 1 N N P A A A P 
12 9 M 1 1 1 1 2 2 2 2 2 2 2 1 1 N N P A A A P 
13 38 M 2 1 1 1 2 2 2 2 2 2 2 1 1 N N A A A A A 
14 39 M 2 1 1 1 2 2 2 2 2 2 2 1 1 N N A A A A A 
15 36 M 2 1 1 1 2 2 2 2 2 2 2 1 1 N N A A A A A 
16 32 M 2 1 2 1 1 1 2 2 2 2 2 1 2 N N P A A A A 
17 34 M 2 1 1 1 1 2 2 2 2 2 2 1 2 N N A A A A A 
18 31 F 2 1 1 1 2 1 2 2 2 2 2 1 2 N N P A A A A 
19 34 F 2 1 1 1 2 1 2 2 2 2 2 1 2 N N P A A A A 
20 43 F 1 2 1 2 2 2 2 2 2 2 2 2 2 N N A A A A A 
21 29 F 1 2 1 2 2 2 2 2 2 2 2 2 2 N N A A A A A 
22 44 F 1 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
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UBO ONG 
SPINAL  
TUMOUR 
ACOUSTIC 
NEUROMA 
HAMAR
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23 27 F 1 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
24 28 M 2 1 1 2 2 2 2 2 2 2 2 1 2 N N A A A A A 
25 14 M 2 1 1 2 2 2 2 2 2 2 2 2 2 N N A A A A A 
26 22 M 2 1 1 2 2 2 2 2 2 2 2 2 2 N N A A A A A 
27 16 M 2 1 1 2 2 2 2 2 2 2 2 2 2 N N A A A A A 
28 26 F 2 1 1 2 2 2 2 2 2 2 2 1 2 N N A A A A A 
29 22 F 2 1 1 2 2 2 2 2 2 2 2 1 2 N N A A A A A 
30 6 F 2 1 2 1 2 2 2 2 2 2 2 2 2 N N A A A A A 
31 31 M 2 1 2 1 2 2 2 2 2 2 2 2 2 N N A A A A A 
32 38 M 2 1 2 1 2 2 2 2 2 2 2 2 2 N N A A A A A 
33 18 M 2 1 2 1 2 2 2 2 2 2 2 2 2 N N A A A A A 
34 34 F 2 1 2 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
35 21 M 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
36 20 F 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
37 17 M 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
38 26 M 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
39 19 F 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
40 29 M 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
41 18 F 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
42 23 F 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
43 14 M 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
44 17 F 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
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SPINAL  
TUMOUR 
ACOUSTIC 
NEUROMA 
HAMAR
TOMA 
45 14 M 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
46 22 F 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
47 16 M 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
48 27 M 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
49 14 F 2 1 1 1 2 2 2 2 2 2 2 2 2 N N A A A A A 
50 26 F 2 1 1 1 2 2 2 2 2 2 2 2 2 N N A A A A A 
51 22 M 2 1 1 1 2 2 2 2 2 2 2 2 2 N N A A A A A 
52 14 F 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
53 15 M 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
54 18 M 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
55 18 F 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
56 11 F 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
57 14 M 2 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
58 11 M 2 1 1 2 2 2 2 2 2 2 2 2 2 N N A A A A A 
59 26 M 2 1 1 2 2 2 2 2 2 2 2 2 2 N N A A A A A 
60 15 M 2 1 1 2 2 2 2 2 2 2 2 1 2 N N A A A A A 
61 36 F 1 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
62 37 F 1 1 1 1 2 2 2 2 2 2 2 1 2 N N P A A A A 
63 13 F 1 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
64 22 M 1 1 1 1 2 2 2 2 2 2 2 1 2 N N P A A A A 
65 16 F 1 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
66 18 M 1 1 1 1 2 2 2 2 2 2 2 1 2 N N A A A A A 
MASTER CHART 2: TUBEROUS SCLEROSIS 
 
S.NO AGE SEX FH/O AF ASH SHAG KOENEN CALM CONFET SZ RSZ ENAMEL MR DEL LD MICRO EEG CT MRI 
TUBER SEN SEGA 
1 11 M 2 1 1 1 2 2 1 1 1 1 2 2 1 2 N 2 P A A 
2 12 F 2 1 1 1 2 2 1 1 1 1 2 2 2 2 N 2 P A A 
3 15 M 1 1 1 1 1 1 2 1 1 1 1 1 1 1 AB 2 A A A 
4 14 F 1 1 1 1 1 1 2 1 1 1 1 1 1 1 AB 2 A A A 
5 34 F 2 1 1 1 1 1 2 1 1 1 1 2 1 2 AB 1 A A P 
6 18 F 2 1 1 1 2 2 2 1 1 1 1 2 1 2 N 2 A A A 
7 17 F 2 1 1 1 2 2 2 1 1 1 1 2 1 2 N 2 A A A 
8 29 F 2 1 1 1 1 2 2 1 1 1 1 2 1 2 AB 2 A P A 
9 28 F 2 1 1 1 1 2 2 1 1 1 1 2 1 2 AB 2 A P A 
10 26 F 2 1 1 1 2 2 2 1 1 1 1 2 1 2 AB 2 A P A 
11 11 F 2 1 1 1 2 2 2 1 1 2 2 2 2 2 N 2 P A A 
12 13 M 2 1 1 1 2 2 2 1 1 2 2 2 2 2 N 2 A A A 
13 16 F 2 1 1 2 2 2 2 1 2 2 2 2 2 2 N 2 A A A 
14 6 F 2 1 1 1 2 2 2 1 2 2 2 2 2 2 N 2 A A A 
15 9 F 2 1 1 1 2 2 2 1 2 2 2 2 2 2 N 2 A A A 
16 7 M 2 1 1 2 2 2 2 2 2 2 2 2 2 2 N 2 A A A 
17 26 M 2 1 2 2 2 2 2 2 2 2 2 2 2 2 N 2 A A A 
18 38 M 2 1 2 2 2 2 2 2 2 2 2 2 2 2 N 2 A A A 
 
 
 
 
 
 
 
 
 
MASTER CHART 3: OTHER NEURO CUTANEOUS SYNDROMES 
 
 
 
 
 
S.NO AGE SEX NC F/H PW NAVE SKIN MR SZ WEAK ATAXIA HFA EYE MRI EEG 
1 13 F SW 2 1 2 2 1 1 2 2 2 1 AB AB 
2 32 F SW 2 1 2 2 2 2 2 2 2 1 N N 
3 18 M SW 2 1 2 2 2 1 2 2 2 1 AB AB 
4 60 F SW 2 1 2 2 2 1 2 2 2 1 AB AB 
5 13 M AT 1 2 2 2 1 1 1 1 2 1 AB AB 
6 8 F AT 1 2 2 2 2 2 2 1 2 1 AB N 
7 9 F AT 2 2 2 2 2 2 2 1 2 1 AB N 
8 45 F GM 2 2 1 2 2 2 2 2 2 2 N N 
9 31 M GM 2 2 1 2 2 1 2 2 2 2 N N 
10 30 F EN 2 2 1 2 2 2 2 2 2 2 N N 
11 35 M EN 2 2 1 2 2 1 2 2 2 2 N N 
12 10 M ITO 2 2 2 1 1 1 2 2 2 2 AB N 
13 11 F XP 2 2 2 1 1 2 2 2 2 1 AB N 
14 28 M ED 2 2 2 1 2 2 2 2 2 1 N N 
15 12 M HHA 2 2 2 2 2 1 2 2 1 2 AB AB 
16 10months F IP 2 2 2 1 2 1 2 2 2 2 AB AB 
KEYS TO MASTER CHART 
 
1   :  PRESENT 
2   : ABSENT 
M   : MALE 
F   : FEMALE 
N   : NORMAL 
P   :  PRESENT 
AB   : ABNORMAL 
FH   : FAMILY HISTORY 
AF   : ANGIO FIBROMA 
ASH   : ASH LEFF MACCULE 
ATAXIA  : CEREBELLAR ATAXIA 
BONY   : SKELETAL ABNORMALITIES 
CALM  : CAFÉ  AU LAIT 
CONFET  : CONFETTI LESIONS 
CT   : COMPUTARISED TOMOGRAPHY 
DEL   : DEVELOPMENT DELAY 
ED   : EHLER DANLOS SYNDROME 
EEG   : ELECTRO ENCEPHALOGRAPHY 
EN   : EPIDERMAL NAEVUS 
ENAMEL  : ENAMEL PITS 
EYE   : EYE ABNORMALITIES 
FAT   : HEMIFACIAL ATROPHY 
FRC   : FRECKLE 
GM   : GIANT MELANOCYTIC NAEVUS 
HEAR   : HEARING LOSS 
HHA   : HERIDITARY HEMIFACIAL ATROPHY 
IP   :  INCONTINENTIA PIGMENTI 
ITO   : HYPOMELANOSIS OF ITO 
KOENEN  : KOENEN SUB UNGAL FIBROMA 
LD   : LEARNING DISABILITY 
LISCH  : LISCH NODULES 
MICRO  : MICROCEPHALY 
MR   : MENTAL RETARDATION 
MRI   : MAGNETIC RESONANCE IMAGE 
NAVI   : NAEVI 
NC   : NEUROCUTANEOUS SYNDROME 
NF   : NEURO FIBROMA 
ONG   : OPTIC NERVE GLICOMA 
PARESIS  : WEAKNESS OF LIMBS 
PE   : PAPILLEDEMA 
PW   : PORT WINE STAIN 
PX   : PLEXIFORM NEURO FIBROMA 
REFSZ  : INTRACTABLE SEIZURES 
SEGA   : SUBEPENDYMAL GIANT ALL ASTROCYTOMA 
SHAG   : SHAGREEN PATCH 
SKIN   : OTHER SKIN LESIONS 
SW   : STURGE WEBER SYNDROME 
SZ   : SEIZURES 
TUBER  : CORTICAL TUBERS 
UBO   : UNIDENTIFIED BRIGHT OBJECTS 
XP   : XERODERMA PIGMENTOSUM 
 
 
 
 
 
 
 

  
 
NEURO FIBROMATOSIS  
 
 
 
Café au lait macules 
 
 
 
 
Lisch nodules 
 
 
 
 
PLEXIFORM NEURO FIBROMAS 
 
 
      
 
 
 
 
 
 
 
 
NEUROIMAGING IN NEUROFIBROMATOSIS 
 
   
Spinal cord compression 
 
 
Optic nerve glioma 
 
 
Acoustic Schawanoma 
TUBEROUS SCLEROSIS 
 
 
ASH LEAF MACULE IN TSC 
 
 
SHAGREEN PATCH IN TSC 
 
 
ADENOMA SABECUM 
 
IMAGING IN TUBEROUS SCLEROSIS 
 
 
  
SUB EPENDDYMAL NODULES 
 
 
 
 
CORTICAL TUBER 
 
 
 
STURGE WEBER SYNDROME 
 
 
 
Port wine stain 
 
 
 
 
Pariet occiptal Calcifications and atrophy  
 
 
 
 
ATAXIA TELANGIECTASIA 
 
 
 
Conjuctival Telangiectasia 
 
 
 
 
Cerebellar Atrophy 
 
XERODERMA PIGMENTOSA 
 
 
 
  Incontinentia Pigmenti 
 
Epidermal Naevus Syndrome 
 
 
PARRY ROMBERG SYNDROME-IMAGING 
 
 
Hemifacial atrophy with ipsilateral hemispheric atrophy 
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